STAT+: Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough
Pfizer (PFE) and BioNTech (BNTX) moved Wednesday to widen access to Covid-19 vaccines by striking a production deal with a South African company, but the effort was quickly panned by patient advocates who argued the arrangement doesn’t go far enough.
In a ballyhooed announcement, the drug makers said they contracted with The Biovac Institute, a vaccine maker backed in part by the South African government, to assemble the final stages of their Covid-19 vaccine, a process known in the pharmaceutical industry as “fill-and-finish.” From there, more than 100 million finished doses will be supplied exclusively to all 55 African Union countries annually.
Continue to STAT+ to read the full story…
